TD Waterhouse Canada Inc. Lowers Holdings in Stryker Corporation $SYK

Key Points

• TD Waterhouse Canada reduced its Stryker holdings by 1.5% in the second quarter, selling 3,271 shares and retaining 210,670 shares valued at approximately $66 million. Institutional investors collectively own 77.09% of Stryker.
• Stryker reported quarterly earnings of $3.69 per share, beating estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, yielding about 1.1% annually.
• Analysts maintain a generally positive outlook, with Stryker holding a consensus “Moderate Buy” rating and an average price target of $386.28. However, insiders sold roughly $118.2 million of stock over the past 90 days, including a $100.8 million sale by director Ronda Stryker.

TD Waterhouse Canada Inc. reduced its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 210,670 shares of the medical technology company's stock after selling 3,271 shares during the period. TD Waterhouse Canada Inc. owned approximately 0.05% of Stryker worth $66,002,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in SYK. Premier Path Wealth Partners LLC grew its position in Stryker by 10.8% during the second quarter. Premier Path Wealth Partners LLC now owns 2,001 shares of the medical technology company's stock worth $630,000 after buying an additional 195 shares in the last quarter. NEOS Investment Management LLC boosted its position in shares of Stryker by 12.4% during the 2nd quarter. NEOS Investment Management LLC now owns 55,637 shares of the medical technology company's stock valued at $17,517,000 after acquiring an additional 6,146 shares during the last quarter. AXQ Capital LP boosted its position in shares of Stryker by 35.8% during the 2nd quarter. AXQ Capital LP now owns 1,944 shares of the medical technology company's stock valued at $612,000 after acquiring an additional 513 shares during the last quarter. KFG Wealth Management LLC grew its holdings in shares of Stryker by 10.4% during the second quarter. KFG Wealth Management LLC now owns 1,737 shares of the medical technology company's stock worth $547,000 after purchasing an additional 163 shares in the last quarter. Finally, Strengthening Families & Communities LLC grew its holdings in shares of Stryker by 0.7% during the second quarter. Strengthening Families & Communities LLC now owns 7,750 shares of the medical technology company's stock worth $2,440,000 after purchasing an additional 52 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

NYSE SYK opened at $308.07 on Friday. The company has a 50-day simple moving average of $329.43 and a two-hundred day simple moving average of $329.92. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The firm has a market cap of $118.17 billion, a price-to-earnings ratio of 31.92, a PEG ratio of 1.95 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 15.03 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio is 36.48%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SYK. Citigroup reaffirmed a "buy" rating on shares of Stryker in a research note on Thursday, August 13th. BTIG Research decreased their price target on shares of Stryker from $371.00 to $358.00 and set a "buy" rating on the stock in a report on Friday, July 31st. UBS Group began coverage on shares of Stryker in a research report on Tuesday, July 28th. They set a "buy" rating and a $400.00 price objective on the stock. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stryker in a report on Friday, July 31st. Finally, Wolfe Research lowered shares of Stryker from an "outperform" rating to a "peer perform" rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.

Insider Transactions at Stryker

In related news, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda Stryker sold 300,000 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director owned 2,301,375 shares of the company's stock, valued at $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 351,267 shares of company stock worth $118,197,701. Insiders own 4.60% of the company's stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source